. In vitro effects of supernatants generated from particle ZrO2 NPs preparations. Particle stock suspensions of ZrO2-TODS, ZrO2-Acryl, ZrO2-PGA, and ZrO2-APTS were subjected to centrifugation (28,000 g, 8 h) to obtain particle-free supernatants (SUP). Volumes equivalent to the 180 μg/mL concentration (c.f. Figure 4) were then diluted in F-12K medium or KRPG buffer and applied to NR8383 macrophages. (ns) not significant, (CTL) untreated control cells. Figure S2 . Size distribution of rat serum albumin-coated ZrO2 particles as prepared for intratracheal administration in rats. Particles were buffered with 25 mM HCO3 − and 5% CO2. Measurements were carried out with optical particle tracking and NanoSight Software NTA 2.2 (Minton Park Amesbury, Wiltshire SP4 7RT, UK). Figure S3 . Size distribution of ZrO2 nanoparticles dispersed in 0.9% NaCl/PBS as used for an administration study in ovalbumin-sensitized mice. (a) ZrO2-PGA, (b) ZrO2-TODS, (c) ZrO2-APTS, and (d) ZrO2-Acryl. Measurements were carried out with optical particle tracking and NanoSight Software NTA 3.1 (Minton Park Amesbury, Wiltshire SP4 7RT, UK). Table S1 . Characteristics of zirconia nanoparticles as published by the NanoGEM consortium. Data are taken from references [23, 24] cited in the main text.
